Compound for inhibiting and inducing degradation of EGFR kinase
US12410192B2 · kind B2 · utility
0Cited by
0References
20Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 16, 2020 |
| Grant date | Sep 9, 2025 |
| Priority date | — |
| Expiry date | Nov 19, 2042 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided is an EGFR kinase inhibitor according to general formula (I) and a pharmaceutical composition containing the inhibitor. The invention can be used to treat diseases related to EGFR kinase, such as cancer. Also provided is a preparation and use of the above inhibitor.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.